AprilBio 2026 Q1: Evommune Milestone Revenue and 95 Billion KRW Cash Holdings

Recognized $500,000 milestone revenue from Evommune technology transfer in Q1 2026 (725 million KRW)
Total financial assets of 95.01 billion KRW: cash 6.43B, short-term instruments 76.51B, long-term instruments 10B
Debt ratio extremely low at 1.01%
Share capital 23,342 million KRW, total equity 97,895 million KRW
APB-R3 phase 2a completed; APB-A1 phase 1b ongoing
R&D expenses 1.36 billion KRW (187.6% of revenue)
No share buyback/cancellation or dividend